Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsoutcomeRheumatoid arthritisrheumatologySafety

EULAR 2015: Biology of Fatigue Rooted in Genes, Cytokines, Free Radicals

Thomas R. Collins  |  August 17, 2015

ROME, Italy—Fatigue, a problem experienced frequently by patients with rheumatic diseases, is best thought of as a survival mechanism and as a single phenomenon, not a condition that comes in a variety of forms, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Gene Regulated…

Filed under:ConditionsEULAR/OtherMeeting ReportsResearch Rheum Tagged with:CytokinesEULARfatiguegeneResearchRheumatic Disease

Catastrophic Antiphospholipid Syndrome with Pulmonary Hemorrhage: A Case Report

Joy-Ann Tabanor, MD, Hyun Bae, MD, Girish Sonpal, MD, & Karlene Williams, MD  |  August 17, 2015

Antiphospholipid syndrome (APS) is an autoimmune condition characterized by hypercoagulability often manifested as recurrent thrombosis or pregnancy complications, with persistently circulating antiphospholipid (aPL) antibodies or lupus anticoagulant. Catastrophic APS (CAPS), also known as Asherson syndrome, occurs in less than 1% of cases of APS and involves occlusive microangiopathy in at least three organ systems.1 Case…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Antiphospholipid Antibody Syndrome (APS)catastrophic antiphospholipid syndromeClinicalDiagnosishemorrhageHughes Syndromeoutcomepatient carePulmonary

Precision Medicine in Rheumatology May Improve Diagnosis, Disease Classification

Richard Quinn  |  August 7, 2015

In an interview with The Rheumatologist, J. Larry Jameson, MD, PhD, discusses the benefits and complications of precision medicine for rheumatologists and their patients, including advances in genetics, diagnostic tools and targeted treatments…

Filed under:Practice Support Tagged with:Personalized medicinePractice ManagementPrecision Medicinerheumatology

Phase 3 Studies Evaluate Lesinurad for Gout Treatment

Michele B. Kaufman, PharmD, BCGP  |  July 15, 2015

For 12 months, two studies examined the use of lesinurad in combination with allopurinol to treat gout, with patients achieving reduced serum uric acid levels and demonstrating no severe toxicity.

Filed under:ConditionsDrug UpdatesEULAR/OtherGout and Crystalline ArthritisMeeting Reports Tagged with:AllopurinolEULARGoutlesinurad

Prepare NOW for ICD-10 Medical Coding Transition

Prepare NOW for ICD-10 Medical Coding Transition

Kimberly Retzlaff  |  July 14, 2015

The ICD-10 page on the Centers for Medicare & Medicaid Services (CMS) website features a countdown clock that shows the time left until Oct. 1, 2015, the date on which compliance with the new code set becomes mandatory. By the time this issue goes to press, the clock will read 90 or fewer days. Time…

Filed under:Billing/CodingPractice Support Tagged with:BillingCodingDocumentationICD-10medicalPractice Managementrheumatologisttransition

How Non-Transferable EHRs Have Affected Physician Practices

Simon M. Helfgott, MD  |  July 13, 2015

Full disclosure: I am not a rabid fan of dogs. None rank among my best friends. Perhaps my antipathy stems from a memorable childhood event, when I was chased down the street where I lived by a neighbor’s large and not-so-friendly hound. He seemed to be twice my size, and this explains why I may…

Filed under:EMRsOpinionPractice SupportRheuminationsSpeak Out RheumTechnology Tagged with:electronic health recordinformation technologypatient carephysician practice

Studies Challenge Conventional Infliximab Protocols in IBD

Laura Newman  |  July 10, 2015

NEW YORK (Reuters Health)—Dose optimization of infliximab is needed much earlier in ulcerative colitis than in Crohn’s disease, a single-center retrospective study reveals. “We compared the rates of dose increases over a fairly lengthy period of time,” said Dr. Mark Silverberg, the study’s senior author from the Mount Sinai Hospital in Toronto. “Patients with ulcerative…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic Conditions Tagged with:Crohn's diseaseinflammatory bowel diseaseinfliximabulcerative colitis

EULAR 2015: The Biology of Fatigue

Thomas R. Collins  |  July 1, 2015

ROME, Italy—Fatigue, a problem experienced frequently by patients with rheumatic diseases, is best thought of as a survival mechanism and as a single phenomenon, not a condition that comes in a variety of forms, an expert said in a session at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). Gene Regulated…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:EULAR

Lungs Are Particularly Vulnerable in Patients with Systemic Rheumatic Disease

Lara C. Pullen, PhD  |  June 29, 2015

In an observational study, physicians found that systemic rheumatic disease exacerbation and treatment-related infections were often related to the lungs…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:critical care managementInfectionlungrheumatologySystemic Rheumatic Diseases

  • « Previous Page
  • 1
  • …
  • 115
  • 116
  • 117
  • 118
  • 119
  • …
  • 137
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences